Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMPNASDAQ:APVONASDAQ:BPTHNASDAQ:HILS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMPAdamis Pharmaceuticals$1.28$0.75▼$26.18$7.26M1.27811,695 shs119,800 shsAPVOAptevo Therapeutics$4.60-6.5%$0.96$4.30▼$658.60$37.30M6.0671,389 shs136,053 shsBPTHBio-Path$0.18-5.3%$0.16$0.12▼$4.55$1.50M-0.141.25 million shs34,359 shsHILSHillstream BioPharma$1.43+5.3%$1.34$0.19▼$2.65$25.17M3.081.39 million shs5,776 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMPAdamis Pharmaceuticals0.00%0.00%0.00%0.00%0.00%APVOAptevo Therapeutics-6.50%+1,110.53%+651.63%+28.13%-99.54%BPTHBio-Path-5.26%+5.88%+28.57%-2.70%-90.58%HILSHillstream BioPharma+5.33%-3.38%+19.18%-5.30%-68.71%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMPAdamis PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAPVOAptevo Therapeutics2.1405 of 5 stars3.54.00.00.02.10.00.6BPTHBio-Path2.002 of 5 stars3.50.00.00.02.60.01.3HILSHillstream BioPharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMPAdamis Pharmaceuticals 0.00N/AN/AN/AAPVOAptevo Therapeutics 3.00Buy$10,952.00237,986.96% UpsideBPTHBio-Path 3.00Buy$20.0011,011.11% UpsideHILSHillstream BioPharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMPAdamis Pharmaceuticals$4.76M0.00N/AN/A($1.26) per share0.00APVOAptevo Therapeutics$3.11M11.99N/AN/A$3.26 per share1.41BPTHBio-PathN/AN/AN/AN/A$0.71 per shareN/AHILSHillstream BioPharmaN/AN/AN/AN/A$0.48 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMPAdamis Pharmaceuticals-$26.48MN/A0.00N/AN/A-502.73%-420.53%-256.87%N/AAPVOAptevo Therapeutics-$24.13MN/A0.00N/AN/AN/A-488.93%-152.51%8/14/2025 (Estimated)BPTHBio-Path-$16.08MN/A0.00N/AN/AN/A-2,842.40%-337.48%N/AHILSHillstream BioPharma-$8.47M-$0.72N/AN/AN/AN/A-188.44%-149.61%N/ALatest BPTH, HILS, ADMP, and APVO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025APVOAptevo Therapeutics-$4.21-$4.39-$0.18-$4.39N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMPAdamis PharmaceuticalsN/AN/AN/AN/AN/AAPVOAptevo TherapeuticsN/AN/AN/AN/AN/ABPTHBio-PathN/AN/AN/AN/AN/AHILSHillstream BioPharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMPAdamis PharmaceuticalsN/A0.230.19APVOAptevo TherapeuticsN/A1.721.72BPTHBio-PathN/A0.860.86HILSHillstream BioPharmaN/A3.013.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMPAdamis Pharmaceuticals38.55%APVOAptevo Therapeutics8.06%BPTHBio-Path5.74%HILSHillstream BioPharma13.36%Insider OwnershipCompanyInsider OwnershipADMPAdamis Pharmaceuticals1.30%APVOAptevo Therapeutics0.01%BPTHBio-Path0.72%HILSHillstream BioPharma30.24%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMPAdamis Pharmaceuticals119.36 million9.24 millionOptionableAPVOAptevo Therapeutics508.11 million1.46 millionNot OptionableBPTHBio-Path108.31 million5.73 millionOptionableHILSHillstream BioPharma117.60 million12.28 millionNot OptionableBPTH, HILS, ADMP, and APVO HeadlinesRecent News About These CompaniesPolice identify 41-year-old killed in Winton Hills shootingSeptember 22, 2024 | cincinnati.comHill & Smith PLC HILSApril 17, 2024 | morningstar.comKiromic BioPharma Inc Ordinary Shares KRBPOctober 31, 2023 | morningstar.comHillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc.September 22, 2023 | finance.yahoo.comDawson James Securities Announces October Date for 8th Annual Small Cap Growth ConferenceSeptember 21, 2023 | finance.yahoo.comHillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic PruritisSeptember 11, 2023 | finance.yahoo.comHillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13September 8, 2023 | finance.yahoo.comHillstream – Drug Maker Licenses Critical New Technology In Fight Against CancerAugust 30, 2023 | benzinga.comNMTRQ 9 Meters Biopharma, Inc.August 25, 2023 | seekingalpha.comHillstream BioPharma to Present at the Sidoti Micro-Cap Virtual Conference on August 16-17, 2023August 9, 2023 | finance.yahoo.comHillstream Advances Next-Gen Multispecific Antibodies for Solid Tumors with Lead HER2/HER3 Program, HSB-3215July 20, 2023 | finance.yahoo.comChange of direction at Hillstream driven by established scienceJuly 13, 2023 | thepharmaletter.comHillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and BiologicsJuly 10, 2023 | finance.yahoo.comHillstream announces new collab to boost early stage researchJuly 7, 2023 | thepharmaletter.comHillstream BioPharma Licenses Technology to Develop Proprietary HER2 and HER3 Antibody Drug Conjugates against Drug-Resistant Breast, Lung, Gastric, and Ovarian CancersJuly 6, 2023 | finance.yahoo.comHILS - Hillstream BioPharma, Inc.June 9, 2023 | finance.yahoo.comHillstream BioPharma Strengthens its Board of Directors with Appointment of Kelly AndersonMay 15, 2023 | finance.yahoo.comHillstream BioPharma, Inc.: Hillstream BioPharma Announces Closing of Public Offering of Common StockMay 4, 2023 | finanznachrichten.deHillstream BioPharma Announces Closing of Public Offering of Common StockMay 2, 2023 | finance.yahoo.comHillstream BioPharma to Present at Upcoming May 2023 Investor and Industry ConferencesMay 2, 2023 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBPTH, HILS, ADMP, and APVO Company DescriptionsAdamis Pharmaceuticals NASDAQ:ADMPAdamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.Aptevo Therapeutics NASDAQ:APVO$4.60 -0.32 (-6.50%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$4.56 -0.04 (-0.98%) As of 04:35 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Bio-Path NASDAQ:BPTH$0.18 -0.01 (-5.26%) As of 05/28/2025 03:49 PM EasternBio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.Hillstream BioPharma NASDAQ:HILS$1.43 +0.07 (+5.33%) As of 05/27/2025Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) and targeted immuno-oncology novel biologics for the treatment drug resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-3215, an anti-HER2 monoclonal antibody candidate; and HSB-1940, a Quatrabody that is a proprietary IO biologic in development targeting PD-1. The company was incorporated in 2017 and is based in Bridgewater, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
